SRZN
NASDAQ HealthcareSurrozen, Inc. - Common Stock
Biotechnology
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $23.15 |
|---|---|
| 成交量 | 122,454 |
| 市值 | 268.72M |
| 贝塔系数 | 0.590 |
| RSI（14日） | 16.6 超卖 |
| 200日均线 | $20.64 |
| 50日均线 | $28.88 |
| 52周最高 | $35.00 |
| 52周最低 | $7.95 |
| Forward P/E | -5.81 |
| Price / Book | -1.20 |
🎯 投资策略评分
SRZN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (83/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🎈 Over-Hyped (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SRZN in your text
粘贴任何文章、记录或帖子 — 工具将提取 SRZN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.